OVERVIEW OF ACTIVITY

Over 45 pharmaceutical agents with more than 55 distinct FDA-approved indications are currently available for the management of hematologic cancer. This extensive armamentarium of treatment options poses a challenge to clinicians who must maintain up-to-date knowledge about optimal clinical management strategies. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of state-of-the-art clinical management strategies to facilitate best-practice patient care.

LEARNING OBJECTIVES

• Develop an algorithm for the evaluation, classification and risk-stratified treatment of myelodysplastic syndrome (MDS).
• Counsel elderly patients with acute myelogenous leukemia (AML) about the efficacy and safety of available treatment options.
• Apply emerging data with novel agents and regimens to the treatment of patients with newly diagnosed or relapsed/refractory indolent and aggressive non-Hodgkin lymphomas (NHL).
• Appraise the role of maintenance therapy in the management of follicular or mantle-cell lymphoma.
• Integrate emerging data with monoclonal antibodies into the evidence-based treatment of chronic lymphocytic leukemia (CLL).
• Communicate the benefits and risks of proteasome inhibitors and IMiD^®-based therapeutic regimens to patients with newly diagnosed multiple myeloma (MM).
• Formulate up-to-date induction and consolidation treatment strategies for patients with acute promyelocytic leukemia (APL).

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/HOU.

This program is supported by educational grants from Eisai Inc, Genentech BioOncology/Biogen Idec, Genzyme Corporation, GlaxoSmithKline and Millennium Pharmaceuticals Inc.

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS
Gail J Roboz, MD
- Select publications

Stephanie A Gregory, MD
- Select publications

Sundar Jagannath, MD
- Select publications

Guillermo Garcia-Manero, MD
- Select publications

Hematologic Oncology Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office